MX355316B - Metabolitos de trans - clomifeno y usos de los mismos. - Google Patents

Metabolitos de trans - clomifeno y usos de los mismos.

Info

Publication number
MX355316B
MX355316B MX2014000825A MX2014000825A MX355316B MX 355316 B MX355316 B MX 355316B MX 2014000825 A MX2014000825 A MX 2014000825A MX 2014000825 A MX2014000825 A MX 2014000825A MX 355316 B MX355316 B MX 355316B
Authority
MX
Mexico
Prior art keywords
metabolites
cancer
clomiphene
trans
elevated
Prior art date
Application number
MX2014000825A
Other languages
English (en)
Other versions
MX2014000825A (es
Inventor
S Podolski Joseph
D Wiehle Ronald
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46724628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355316(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2014000825A publication Critical patent/MX2014000825A/es
Publication of MX355316B publication Critical patent/MX355316B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a metabolitos de trans-clomifeno sustancialmente puros. La invención también se refiere a composiciones farmacéuticas que comprenden estos metabolitos y su uso en el tratamiento de trastornos incluyendo hipogonadismo secundario, diabetes tipo 2, colesterol elevado, triglicéridos elevados, emaciación, lipodistrofia, infertilidad femenina y masculina, hipertrofia benigna de la próstata, cáncer de próstata, cáncer de mama, cáncer de ovarios y cáncer de endometrio.
MX2014000825A 2011-08-04 2012-08-03 Metabolitos de trans - clomifeno y usos de los mismos. MX355316B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515278P 2011-08-04 2011-08-04
PCT/US2012/049451 WO2013020017A1 (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof

Publications (2)

Publication Number Publication Date
MX2014000825A MX2014000825A (es) 2014-02-27
MX355316B true MX355316B (es) 2018-04-16

Family

ID=46724628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000825A MX355316B (es) 2011-08-04 2012-08-03 Metabolitos de trans - clomifeno y usos de los mismos.

Country Status (21)

Country Link
US (1) US9981906B2 (es)
EP (2) EP3351527A1 (es)
JP (2) JP6433785B2 (es)
KR (1) KR20140054110A (es)
CN (1) CN103702975B (es)
AU (2) AU2012289964B2 (es)
BR (1) BR112014000908A2 (es)
CA (1) CA2841572C (es)
CL (1) CL2014000268A1 (es)
CO (1) CO6862154A2 (es)
CR (1) CR20140124A (es)
EA (1) EA201490416A1 (es)
HK (1) HK1196349A1 (es)
IL (1) IL230287B (es)
MX (1) MX355316B (es)
MY (2) MY170718A (es)
NI (1) NI201400008A (es)
SG (1) SG10201606425WA (es)
UA (1) UA113291C2 (es)
WO (1) WO2013020017A1 (es)
ZA (1) ZA201400406B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120284764A1 (en) * 2011-05-05 2012-11-08 Keith Ball Method and system for requesting services by a media device
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US10328022B2 (en) 2012-05-31 2019-06-25 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
MX2015005160A (es) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomifeno para uso en terapia de cancer.
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
WO2017123577A1 (en) * 2016-01-12 2017-07-20 Repros Therapeutics Inc. Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions
MX2018010286A (es) * 2016-02-25 2018-09-27 Aspen Park Pharmaceuticals Inc Forma de dosificacion oral de ambos isomeros de clomifeno y metodo para usar los mismos para tratar hipogonadismo secundario.
CA2989364C (en) 2016-04-22 2021-07-20 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2143000C (en) * 1992-09-15 2000-03-28 Alan J. Bitonti Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU2638795A (en) 1994-06-17 1996-01-15 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US6221399B1 (en) 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1998018610A1 (en) 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
BR9809064A (pt) 1997-04-03 2002-01-02 Guilford Pharm Inc Polìmeros biodegradáveis de poliéster de tereftalato-polifosfato, composições, artigos e métodos para fazer e usar os mesmos
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
WO2000005954A1 (en) 1998-07-30 2000-02-10 Stoller Enterprises, Inc. Treatment of plants with salicylic acid and organic amines
ATE355279T1 (de) 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PE20010404A1 (es) 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
WO2001054699A1 (en) 2000-01-28 2001-08-02 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
JP2003534375A (ja) 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
EP1318837B1 (en) 2000-08-11 2004-10-06 Wyeth Method of treating estrogen receptor positive carcinoma
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002030355A2 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CA2777199A1 (en) 2001-07-09 2003-01-23 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2005507886A (ja) 2001-09-21 2005-03-24 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としてのアンドロスタン類
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
EP1848416A4 (en) * 2005-02-04 2008-09-24 Repros Therapeutics Inc METHOD AND MATERIALS USING TRANS-CLOMIPHES FOR TREATING MALE INACCURIBILITY
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
PL383444A1 (pl) 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
CN101309702A (zh) 2005-08-05 2008-11-19 雷普罗斯治疗公司 使用克罗米酚治疗女性不育症的方法及其组合物
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
CA2655997A1 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
JP5196685B2 (ja) 2007-06-26 2013-05-15 メディア パテンツ エセ．エレ． マルチキャストグループを管理する方法と装置
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN104582686A (zh) 2012-08-21 2015-04-29 利普生物药剂公司 反式克罗米酚(trans-clomiphene)调配物和其用途
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Also Published As

Publication number Publication date
IL230287B (en) 2019-07-31
AU2017204171A1 (en) 2017-07-13
JP6433785B2 (ja) 2018-12-05
UA113291C2 (xx) 2017-01-10
EP2744777A1 (en) 2014-06-25
JP2014529584A (ja) 2014-11-13
US20140163114A1 (en) 2014-06-12
MY170718A (en) 2019-08-27
WO2013020017A1 (en) 2013-02-07
BR112014000908A2 (pt) 2017-02-21
CN103702975A (zh) 2014-04-02
CA2841572C (en) 2020-10-13
EA201490416A1 (ru) 2014-11-28
AU2012289964B2 (en) 2017-03-23
CN103702975B (zh) 2016-03-16
CL2014000268A1 (es) 2014-11-14
CA2841572A1 (en) 2013-02-07
NI201400008A (es) 2015-12-10
MY191802A (en) 2022-07-15
AU2012289964A1 (en) 2014-01-30
SG10201606425WA (en) 2016-09-29
EP3351527A1 (en) 2018-07-25
CR20140124A (es) 2014-05-13
MX2014000825A (es) 2014-02-27
JP2019023210A (ja) 2019-02-14
IL230287A0 (en) 2014-03-06
HK1196349A1 (zh) 2014-12-12
US9981906B2 (en) 2018-05-29
NZ621892A (en) 2016-03-31
CO6862154A2 (es) 2014-02-10
KR20140054110A (ko) 2014-05-08
ZA201400406B (en) 2014-11-26

Similar Documents

Publication Publication Date Title
MY191802A (en) Trans-clomiphene metabolites and uses thereof
PH12015500331A1 (en) Trans-clomiphene formulations and uses thereof
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
NZ700928A (en) Dna-pk inhibitors
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
IN2012DN02081A (es)
MX2011007420A (es) Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
IN2012MN02591A (es)
AU2016219704A1 (en) Anti-Notch1 antibodies
MY157120A (en) Stable pharmaceutical composition and methods of using same
AU2012208283A8 (en) Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
IN2014DN06104A (es)
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
NZ706983A (en) Treating soluble coffee
GEP201706626B (en) Synthesis of (s)-nifuratel
MX350392B (es) Aceite de sandalo y sus usos.
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
IN2013DE03665A (es)
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.
UA76841U (en) Feed additive "echinobioactive"
UA52377U (en) hydrophobic composition

Legal Events

Date Code Title Description
FG Grant or registration